Physician profile
Devang Patel
NPI 1669546222
$6,595.88
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,301 · 2020: $743 · 2021: $1,036 · 2022: $652 · 2023: $501 · 2024: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,163.85 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $1,012.65 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $639.20 | 2019-2024 | Libtayo |
| Glaxosmithkline, LLC. | $528.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.54 | 2019-2022 | |
| Mylan Specialty L.P. | $265.42 | 2019-2020 | |
| United Therapeutics Corporation | $263.00 | 2019-2021 | |
| Insmed, INC. | $238.25 | 2019-2020 | |
| Genentech USA, INC. | $209.75 | 2019 | |
| Genzyme Corporation | $143.30 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $138.27 | 2019-2020 | |
| Kite Pharma, INC. | $125.00 | 2024 | Yescarta |
| Seagen INC. | $125.00 | 2023 | Adcetris |
| Janssen Biotech, INC. | $125.00 | 2022 | |
| Mirati Therapeutics, INC. | $125.00 | 2023 | Krazati |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $124.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $124.95 | 2019 | |
| Dova Pharmaceuticals | $124.87 | 2021 | |
| Boston Scientific Corporation | $113.64 | 2024 | Watchman Flx |
| Amgen INC. | $109.99 | 2019 | |
| Pulmonx Corporation | $105.03 | 2020 | |
| Mallinckrodt Enterprises LLC | $72.34 | 2019 | |
| Merck Sharp & Dohme LLC | $72.06 | 2019 | |
| Circassia INC. | $50.16 | 2019 | |
| Advanced Respiratory, INC | $43.67 | 2019-2021 | |
| Resmed Corp | $37.84 | 2019 | |
| Grifols USA, LLC | $25.55 | 2019 | |
| Pfizer INC. | $16.60 | 2019 | |
| Daiichi Sankyo INC. | $14.50 | 2019 | |
| Philips North America LLC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devang Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.